Atopic Dermatitis (Eczema) clinical trials at University of California Health

18 in progress, 9 open to eligible people

Showing trials for

  • Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

    open to eligible people ages 6-11

    This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to <12 years of age who have moderate-to-severe eczema. Research study participants who meet the study criteria will be assigned by chance (like the flip of a coin) to receive either abrocitinib test medicine or placebo (pretend medicine that looks just like the test medicine) for 16 weeks. The study will last for about 24 weeks in total.

    at UCSD

  • Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

    open to eligible people ages 18 years and up

    The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).

    at UCLA

  • IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

    open to eligible people ages 18-74

    The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

    at UCLA

  • Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

    open to eligible people ages 18-65

    This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.

    at UC Davis

  • Molecular Signatures of Cutaneous Dupilumab Response

    open to eligible people ages 18 years and up

    This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

    at UCSF

  • Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

    open to eligible people ages 12 years and up

    This is a Phase 1b, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S. hominis A9 (ShA9) topical application as a treatment for atopic dermatitis (AD). The trial will enroll adults and adolescents with atopic dermatitis who are culture positive for S. aureus colonization. The primary safety objective of this study is to compare the safety profile of ShA9 to placebo (vehicle) over 14 weeks of application, which includes an initial two-week period of co-treatment with topical corticosteroids (TCS). The primary efficacy objective of this study is to assess the ability of ShA9, compared to placebo (vehicle), to prolong the period of atopic dermatitis control over 12 weeks after conclusion of an initial two-week period of co-treatment with TCS.

    at UCSD

  • Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

    open to eligible females

    The goal of this observational study is to learn about exposure to tralokinumab during pregnancy, as well as atopic dermatitis (AD) during pregnancy. The main question the study aims to answer is whether pregnant people who have been exposed to tralokinumab during pregnancy experience any differences in pregnancy and infant outcomes compared to women with atopic dermatitis who have not been exposed to tralokinumab during pregnancy. Participants are not required to take tralokinumab during the study. Participants will be asked to: - Complete 1-3 phone interviews during pregnancy and 1-2 phone interviews after delivery - Release medical records for pregnancy and for their child - Complete an online survey about their baby's development at 4 months and 12 months of age - May be asked to have a study doctor examine their child All information is collected remotely, and no visits to the study site are required.

    at UCSD

  • Sodium in the Skin and Atopic Dermatitis

    open to eligible people ages 50 years and up

    The goal of this observational study is to understand factors associated with skin sodium storage in healthy adults and people with atopic dermatitis ages 50 and above. The study is designed to test whether diet and skin barrier function are associated with skin sodium concentration and whether skin sodium concentration is linked to atopic dermatitis and immune profiles over time. Participants will be asked to complete questionnaires, provide bio samples, and undergo non-contrast sodium MRI at 2-3 time points over 3-24 months.

    at UCSF

  • Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

    open to eligible people ages 12 years and up

    The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. Additionally, patient-specific factors (such as age, skin color, AD flare triggers, previous treatment responses, comorbid conditions, and the extent and site of lesions) will be assessed to better characterize the impact on the treatment journey across a broad age range and diverse geographic regions. The study will be conducted across 10 countries in 4 different geographical regions, with a follow-up period of 5 years.

    at UCLA

  • Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

    Sorry, not currently recruiting here

    This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.

    at UCSD

  • Barzolvolimab in Patients With Atopic Dermatitis

    Sorry, in progress, not accepting new patients

    The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis

    at UCLA

  • JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.

    at UCLA

  • Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

    Sorry, in progress, not accepting new patients

    The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

    at UC Davis UC Irvine UCLA

  • Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

    Sorry, in progress, not accepting new patients

    The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

    at UC Irvine

  • Dietary Salt on the Severity of Eczema

    Sorry, not yet accepting patients

    The goal of this clinical trial is to evaluate the feasibility of low-sodium diet to improve eczema severity. The main questions it aims to answer are: - Does a low-sodium diet improve eczema severity? - How does a low-sodium diet impact skin sodium concentration? - Is skin sodium concentration associated with eczema severity? Researchers will ask all participant to follow a low-sodium diet, then compare sodium tablets to a placebo (a look-alike substance that contains no drug) to specifically examine the impact of altering sodium intake. Participants will: - Follow a low-salt diet for the duration of the 24-week study - Take sodium chloride tablets every day for 5 weeks followed by a placebo every day for 5 weeks after a 2-week washout period, or vice versa - Complete up to 4 virtual check-in visits - Visit the clinic 4 times to answer questionnaires, provide bio samples, complete dietary recalls, and undergo non-contrast sodium MRI

    at UCSF

  • Salt Intake on Sodium in the Skin and Inflammatory Skin Disease

    Sorry, not yet accepting patients

    The goal of this clinical trial is to demonstrate the feasibility of a trial that examines the impact of changes in dietary sodium intake on skin sodium levels, atopic dermatitis, and psoriasis. In addition, it aims to generate preliminary data to begin to answer the following questions: 1. Is there an association between skin sodium concentration and atopic dermatitis and psoriasis severity? 2. Are changes in dietary sodium are associated with changes in skin sodium concentration and atopic dermatitis and psoriasis severity? Researchers will compare sodium tablets to a placebo (a look-alike substance that contains no drug) to specifically examine the impact of altering sodium intake. Participants will: - Follow a low-salt diet for the duration of the 13-week study - Take sodium chloride tablets every day for 5 weeks followed by a placebo every day for 5 weeks after a 2-week washout period, or vice versa - Visit the clinic up to 4 times to answer questionnaires, provide bio samples, complete dietary recalls, and undergo non-contrast sodium MRI

    at UCSF

  • Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

    Sorry, not yet accepting patients

    This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis. The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

    at UCSF

  • Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

    Sorry, in progress, not accepting new patients

    TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

    at UC Irvine UCSD

Our lead scientists for Atopic Dermatitis (Eczema) research studies include .

Last updated: